# Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

> **NCT03469713** · PHASE2 · COMPLETED · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 69 (actual)

## Conditions studied

- Renal Cancer Metastatic

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03469713
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-14
- **Primary completion:** 2019-03-04
- **Final completion:** 2021-07-14
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03469713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03469713, "Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03469713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*